{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:42:04Z","timestamp":1789764124620,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.phrs.2019.104590","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T12:22:08Z","timestamp":1575894128000},"page":"104590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia"],"prefix":"10.1016","volume":"153","author":[{"given":"Stefania","family":"Koutsilieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Tzioufa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina-Christina","family":"Sismanoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P.","family":"Patrinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.phrs.2019.104590_bib0005","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2217\/pgs.10.97","article-title":"Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice","volume":"11","author":"Squassina","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2019.104590_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1875692111666131223235548","article-title":"Translating pharmacogenetics and pharmacogenomics: the last 60 years and the rise of collective innovation as a force multiplier for personalized medicine","volume":"12","author":"Cheng","year":"2014","journal-title":"Curr. Pharmacogenomics Person. Med."},{"key":"10.1016\/j.phrs.2019.104590_bib0015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/cpt.976","article-title":"How to consider rare genetic variants in personalized drug therapy","volume":"103","author":"Lauschke","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.phrs.2019.104590_bib0020","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/acem.13027","article-title":"Systematic molecular phenotyping: a path towards precision emergency medicine?","volume":"23","author":"Limkakeng","year":"2016","journal-title":"Acad. Emerg. Med."},{"issue":"7","key":"10.1016\/j.phrs.2019.104590_bib0025","first-page":"588","article-title":"Pharmacogenetics: using genetic information to guide drug therapy","volume":"92","author":"Chang","year":"2015","journal-title":"Am. Fam. Physician"},{"issue":"12","key":"10.1016\/j.phrs.2019.104590_bib0030","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/ejhg.2016.114","article-title":"Role of pharmacogenetics in public health and clinical health care: a SWOT analysis","volume":"24","author":"Kapoor","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.phrs.2019.104590_bib0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pharmthera.2019.01.002","article-title":"Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity","volume":"197","author":"Lauschke","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2019.104590_bib0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/tpj.2013.33","article-title":"The potential impact of pharmacogenetic testing on medication adherence","volume":"13","author":"Haga","year":"2013","journal-title":"Pharmacogenomics J."},{"issue":"7329","key":"10.1016\/j.phrs.2019.104590_bib0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/469156a","article-title":"Bring on the biomarkers","volume":"469","author":"Poste","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2019.104590_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/641089","article-title":"Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice","author":"Lam","year":"2013","journal-title":"ISRN Pharmacol."},{"issue":"7573","key":"10.1016\/j.phrs.2019.104590_bib0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2019.104590_bib0060","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1752-8062.2011.00348.x","article-title":"University of Florida clinical and Translational science institute: transformation and translation in personalized medicine","volume":"4","author":"Nelson","year":"2011","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.phrs.2019.104590_bib0065","series-title":"Genetics Home Reference Handbook: How Can Consumers Be Sure Genetic Testing Is Valid and Useful?","author":"US National Library of Medicine","year":"2014"},{"issue":"6990","key":"10.1016\/j.phrs.2019.104590_bib0070","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature02626","article-title":"Moving towards individualized medicine with pharmacogenomics","volume":"429","author":"Evans","year":"2004","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2019.104590_bib0075","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/clpt.2014.185","article-title":"Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues","volume":"96","author":"Gillis","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.104590_bib0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41525-018-0065-4","article-title":"User considerations in assessing pharmacogenomic tests and their clinical support tools","volume":"3","author":"Mukerjee","year":"2018","journal-title":"NPJ Genom. Med."},{"issue":"9","key":"10.1016\/j.phrs.2019.104590_bib0085","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2014.181","article-title":"Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs","volume":"17","author":"Vivot","year":"2015","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104590_bib0090","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jacbts.2018.06.001","article-title":"Pharmacogenetic labeling of FDA-Approved drugs: a regulatory retrospective","volume":"3","author":"Drozda","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"issue":"9","key":"10.1016\/j.phrs.2019.104590_bib0095","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.xphs.2017.04.051","article-title":"Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions","volume":"106","author":"Klein","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.phrs.2019.104590_bib0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010814-124835","article-title":"Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers","volume":"55","author":"Dunnenberger","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"23","key":"10.1016\/j.phrs.2019.104590_bib0105","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2146\/ajhp150977","article-title":"Evidence and resources to implement pharmacogenetic knowledge for precision medicine","volume":"73","author":"Caudle","year":"2016","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.phrs.2019.104590_bib0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1389200215666140130124910","article-title":"Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process","volume":"15","author":"Caudle","year":"2014","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.phrs.2019.104590_bib0115","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.10475.1","article-title":"Bringing a genomic perspective to the safety of drug treatment in oncology. Version 1","volume":"6","author":"Innocenti","year":"2017","journal-title":"F1000Res"},{"issue":"4","key":"10.1016\/j.phrs.2019.104590_bib0120","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cpt.762","article-title":"Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group","volume":"103","author":"Bank","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2019.104590_bib0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/jpm9020029","article-title":"Primary care physicians\u2019 knowledge, attitudes, and experience with personal genetic testing","volume":"9","author":"Haga","year":"2019","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.phrs.2019.104590_bib0130","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/gtmb.2015.0061","article-title":"Next-generation testing for Cancer risk: perceptions, experiences, and needs among early adopters in community healthcare settings","volume":"19","author":"Blazer","year":"2015","journal-title":"Genet. Test. Mol. Biomark."},{"issue":"2","key":"10.1016\/j.phrs.2019.104590_bib0135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/clpt.2014.97","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype","volume":"96","author":"Relling","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2019.104590_bib0140","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2014.159","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA\u2010B genotypes and phenytoin dosing","volume":"96","author":"Caudle","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2019.104590_bib0145","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"HLA Clinical pharmacogenetics implementation consortium (CPIC) guideline for genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Philips","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2019.104590_bib0150","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.104590_bib0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/pgs.10.169","article-title":"Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase","volume":"12","author":"Georgitsi","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.phrs.2019.104590_bib0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162866","article-title":"A european Spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics","volume":"11","author":"Mizzi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104590_bib0165","article-title":"Sketching the prevalence of pharmacogenomic biomarkers among populations for clinical pharmacogenomics","author":"Patrinos","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.phrs.2019.104590_bib0170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/gim.2016.33","article-title":"Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response","volume":"19","author":"Kozyra","year":"2017","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.104590_bib0175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/tpj.2014.86","article-title":"Pharmacogenomic information in drug labels: European Medicines Agency perspective","volume":"15","author":"Ehmann","year":"2015","journal-title":"Pharmacogenomics J."},{"issue":"8","key":"10.1016\/j.phrs.2019.104590_bib0180","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/pgs.12.48","article-title":"Accuracy of NAT2 SNP genotyping panels to infer acetylator phenotypes in African, Asian, Amerindian and admixed populations","volume":"13","author":"Suarez-Kurtz","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.phrs.2019.104590_bib0185","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2217\/pgs.12.39","article-title":"Application of the FST statistics to explore pharmacogenomic diversity in the Brazilian population","volume":"13","author":"Suarez-Kurtz","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.phrs.2019.104590_bib0190","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3389\/fphar.2019.00830","article-title":"Application of economic evaluation to assess feasibility for reimbursement of genomic testing as part of personalized medicine interventions","volume":"2","author":"Simeonidis","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104590_bib0195","article-title":"Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group","author":"Caudle","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.phrs.2019.104590_bib0200","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1409","article-title":"Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy","author":"Brown","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.104590_bib0205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC\u00ae) guideline for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2019.104590_bib0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.602","article-title":"Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium","volume":"101","author":"van der Wouden","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2019.104590_bib0215","article-title":"ePGA: a web-based information system for translational pharmacogenomics","volume":"11","author":"Liakotaki","year":"2016","journal-title":"PLoS One"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819319085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819319085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:07:08Z","timestamp":1760911628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819319085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":43,"alternative-id":["S1043661819319085"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104590","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104590"}}